Scinai Immunotherapeutics (SCNI) has released an update.
Scinai Immunotherapeutics has announced successful preclinical results for its new anti IL-17A/F VHH antibody fragment, a local treatment for mild to moderate plaque psoriasis, with potential to offer high efficacy with fewer side effects compared to current therapies. The study, conducted by Prof. Amos Gilhar at the Technion, showed that Scinai’s NanoAb treatment reduced key inflammatory markers and improved skin integrity, positioning the company to address the large market of over 13 million patients. With positive results reinforcing previous studies, Scinai plans further in-vivo studies and a first-in-human clinical trial by late 2025.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.
